In re: Reglan Litigation (A-56-14;

 In re: Reglan Litigation (A-56-14; 075269)

          Plaintiffs’ state-law failure-to-warn claims under the
          PLA, based on the alleged inadequate labeling of
          metoclopramide which did not match the brand-name
          labeling and warn of the dangers of the long-term use
          of the drug, are not preempted by federal law, and may
          proceed before the trial court.